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Abstract
Objective:  To  describe  the  results  of  a  long-term  follow-up  of  Bartter  syndrome  patients  treated
with different  drugs.
Method: Patients  were  diagnosed  according  to  clinical  and  laboratory  data.  Treatment  protocol
was  potassium  supplementation,  sodium,  spironolactone,  and  non-steroidal  anti-inﬂammatory
drug.  Patients  who  developed  proteinuria  were  converted  to  angiotensin  conversion  enzyme
inhibitor.  The  variables  evaluated  for  each  drug  were  Z-score  for  weight  and  stature,  protein-
uria,  creatinine  clearance,  gastrointestinal  complaints,  amount  of  potassium  supplementation,
serum  potassium  and  bicarbonate  levels,  and  ﬁndings  of  upper  digestive  endoscopy.
Results: 20  patients  were  included.  Follow-up  was  10.1  ±  5.2  years.  17  patients  received
indomethacin for  5.9  ±  5.3  years;  19  received  celecoxib,  median  of  35  months;  and  ﬁve  received
enalapril,  median  of  23  months.  During  indomethacin,  a  statistically  signiﬁcant  increase  was
observed  in  the  Z-score  for  stature  and  weight,  without  a  change  in  the  creatinine  clearance.
Seven  of  17  patients  had  gastrointestinal  symptoms,  and  upper  digestive  endoscopy  evidenced
gastritis  in  three  patients  and  gastric  ulcer  in  four  patients.  During  celecoxib  use,  a  signiﬁcant
increase was  detected  in  the  Z-score  for  stature  and  weight  and  a  reduction  of  hyperﬁltration;
seven patients  presented  gastrointestinal  symptoms,  and  upper  digestive  endoscopy  evidenced
mild  gastritis  in  three.  During  enalapril  use,  no  signiﬁcant  changes  were  observed  in  the  Z-
score  for  stature,  weight  and  creatinine  clearance.  The  conversion  to  enalapril  resulted  in  a
signiﬁcant  reduction  in  proteinuria.
 Please cite this article as: Nascimento CL, Garcia CL, Schvartsman BG, Vaisbich MH. Treatment of Bartter syndrome. Unsolved issue. J
ediatr (Rio J). 2014;90:512--7.
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Conclusion:  The  authors  suggest  starting  the  treatment  with  celecoxib,  and  replacing  by  ACEi
if necessary,  monitoring  the  renal  function.  The  safety  and  efﬁcacy  of  celecoxib  need  to  be
assessed  in  larger  controlled  studies.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Resumo
Objetivo:  Descrever  os  resultados  de  um  acompanhamento  de  longo  prazo  de  pacientes  com
síndrome de  Bartter  tratados  com  diferentes  medicamentos.
Método:  Pacientes  diagnosticados  segundo  os  dados  clínicos  e  laboratoriais.  Protocolo  de  trata-
mento:  suplementac¸ão  de  potássio,  sódio,  espironolactona  e  medicamento  anti-inﬂamatório
não esteroidal.  Os  pacientes  que  desenvolveram  proteinúria  foram  submetidos  a  inibidor  da  enz-
ima  de  conversão  da  angiotensina.  As  variáveis  avaliadas  durante  o  uso  de  cada  medicamento
foram:  escore  Z  para  peso  e  estatura,  proteinúria,  depurac¸ão  da  creatinina,  queixas  gastroin-
testinais,  quantidade  da  suplementac¸ão  de  potássio,  níveis  séricos  de  potássio  e  bicarbonato  e
achados  da  endoscopia  digestiva  alta.
Resultados:  Foram  incluídos  20  pacientes.  O  acompanhamento  foi  de  10,1±5,2  anos.  No  total,
17 pacientes  receberam  indometacina  por  5,9±5,3  anos,  19  receberam  celecoxib  por  aproxi-
madamente  35  meses  e  cinco  receberam  enalapril  por  aproximadamente  23  meses.  Durante  o
uso  de  indometacina,  observamos  um  aumento  estatístico  signiﬁcativo  no  escore  Z  para  estatura
e  peso,  sem  alterac¸ão  na  depurac¸ão  da  creatinina.  7/17  pacientes  apresentaram  sintomas  gas-
trointestinais,  e  a  endoscopia  digestiva  alta  mostrou  gastrite  em  três  pacientes  e  úlcera  gástrica
em  quatro.  Durante  o  uso  de  celecoxib,  detectamos  um  aumento  signiﬁcativo  no  escore  Z  para
estatura  e  peso  e  uma  reduc¸ão  da  hiperﬁltrac¸ão;  sete  pacientes  apresentaram  sintomas  gas-
trointestinais  e  a  endoscopia  digestiva  alta  mostrou  gastrite  leve  em  três  pacientes.  Durante
o  uso  de  enalapril,  não  observamos  alterac¸ões  signiﬁcativas  no  escore  Z  para  estatura,  peso
e  depurac¸ão  da  creatinina.  A  mudanc¸a da  medicac¸ão  para  enalapril  resultou  em  uma  reduc¸ão
signiﬁcativa na  proteinúria.
Conclusão: Sugerimos  iniciar  o  tratamento  com  celecoxib  e,  caso  necessário,  substituí-lo  por
ACEi, monitorando  a  func¸ão  renal.  A  seguranc¸a e  a  eﬁcácia  do  celecoxib  precisam  ser  compro-
vadas  com  grandes  estudos  controlados.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Bartter  syndrome  (BS)  encompasses  a  group  of  rare  genetic,
autosomal recessive,  renal  tubular  diseases  characte-
rized by  urinary  loss  of  sodium,  potassium,  and  chloride;
hypokalemic metabolic  alkalosis;  high  plasma  levels  of  renin
and aldosterone;  and  high  levels  of  prostaglandins  (PGs)
in blood  and  urine  as  a  secondary  phenomenon.  Clinically
patients present  polyuria,  polydipsia,  failure  to  thrive,  life-
threatening episodes  of  dehydration,  episodes  of  fever,  and
normal or  low  blood  pressure.  Frequently,  pediatricians  are
the ﬁrst  professionals  to  attend  to  these  patients  and  it  is
therefore important  to  be  aware  of  this  condition,  since
prognosis is  better  with  earlier  diagnosis  and  treatment.
There are  different  types  of  BS,  and  clinical  and  laborato-
rial variability  depends  on  the  affected  tubular  carrier.1,2
According  to  the  affected  region,  some  differences  can  be
observed in  the  management  of  the  disease,  for  instance,
type II  BS  is  associated  with  very  mild  hypokalemia,  whereas
in type  IV  BS,  treatment  with  indomethacin  is  much  less
effective.3
s
i
d
sThe  present  study  aimed  to  describe  the  results  of  a  long-
erm follow-up  of  BS  patients  treated  with  different  drugs.
atients and methods
his  retrospective  study,  based  on  a  prospective  protocol,
nrolled patients  with  clinical  and  laboratorial  diagnosis
f BS  from  1993  until  2012,  and  adherent  to  the  treat-
ent, which  was  evaluated  by  adherence  to  scheduled  clinic
ppointments and  serum  bicarbonate  and  potassium  levels.
enetic analysis  is  not  available  in  this  service.
reatment  protocol
he  protocol  was  initially  based  on  electrolytes  sup-
lementation (potassium  and,  in  some  cases,  sodium),
pironolactone, and  the  non-selective  non-steroidal  anti-
nﬂammatory drug  (nsNSAID),  indomethacin.  However,
uring the  period  of  indomethacin  treatment  (1993  to  2003),
ix of  12  (50%)  patients  presented  signiﬁcant  gastrointestinal
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ymptoms;4 and  since  2003,  it  was  decided  to  adopt  a
elective NSAID  (sNSAID),  celecoxib,  in  order  to  avoid  gas-
rointestinal compromise.
Patients who  developed  proteinuria  were  converted  to  an
ngiotensin conversion  enzyme  inhibitor  (ACEi),  enalapril,  in
eplacement to  NSAID.  This  conversion  was  made  during  hos-
italization, since  patients  can  potentially  develop  serious
ypotension with  ACEi.
ariables
he  following  variables  were  evaluated  during  treatment
ith each  drug:  Z-score  for  weight  and  stature,  glomeru-
ar ﬁltration  rate  (GFR)  through  creatinine  clearance  (using
chwartz’s formula,  since  urinary  collection  of  24  hours  is
ifﬁcult, especially  in  polyuric  patients),5 average  potas-
ium supplementation,  and  serum  levels  of  potassium  and
icarbonate. The  presence  of  proteinuria,  gastrointestinal
GI) complaints,  and  ﬁndings  of  upper  digestive  endoscopy
UDE) were  also  evaluated.
In this  study,  hyperﬁltration  was  deﬁned  as  creatinine
learance ≥  145  mL/min/1.73m2BS  (mL/min/1,73  m2Body
urface).6
tatistical  analysis
ata  with  homogeneous  distribution  were  shown  as  mean
nd standard  deviation.  All  others  were  shown  as  median
nd range.  Student’s  t-test  for  paired  samples  was  employed
o compare  variables  with  normal  distribution,  and  the
ilcoxon test  was  used  to  compare  non-normal  distribu-
ion variables.  The  latter  was  also  employed  to  compare  the
icroalbuminuria levels  before  and  after  the  substitution
f celecoxib  to  enalapril.  The  chi-squared  test  was  used  to
ompare the  ﬁndings  in  UDE  in  symptomatic  patients  during
ndomethacin and  celecoxib  use.
The  study  was  approved  by  local  ethics  committee.
esults
wenty  patients  were  included,  of  whom  12  were  females.
ollow-up time  was  10.1  ±  5.2  years,  age  at  diagnosis  had
 median  of  17.5  months  (3--178)  and  at  last  evaluation
as 14.0  ±  5.3  years.  Five  patients  were  born  from  con-
anguineous parents  and  two  patients  were  siblings.  Seven
atients, ﬁve  of  whom  females,  presented  with  polyhy-
ramnio and/or  prematurity,  characteristics  of  neonatal  BS.
eurosensorial deafness  was  observed  in  two  patients  (one
emale), and  they  are  classiﬁed  as  BS  with  deafness.  Eleven
atients showed  characteristics  of  classic  BS.  No  patient  pre-
ented with  hypocalciuria,  thus  excluding  the  diagnosis  of
itelman syndrome.
eriod  of  indomethacin  treatment
eventeen  patients  received  indomethacin  for  5.9  ±  5.3
ears in  a  dosage  of  2.1  ±  0.6  mg/Kg/day  divided  in  three
oses. An  increase  was  observed  in  height-for-age  Z-score,
rom -3.3  ±  -2.1  to  -2.2  ±  1.2  (p  =  0.01),  and  in  weight-
or-age Z-score,  from  median  =  -2.9  (-5.7  --  2.5)  to  median  =
t
r
aNascimento  CL  et  al.
1.05  (-4.9-  2.5)  (p  =  0.0004),  without  a  signiﬁcant  change  in
he creatinine  clearance,  which  varied  from  median  =  105
64-277) to  median  =  144  (71-279)  mL/min/1.73m2BS  (p  =
.34); and  with  metabolic  and  electrolyte  stability.  However,
our patients  had  hyperﬁltration  at  the  beginning  and  eight
resented hyperﬁltration  at  the  end  of  the  treatment.  Seven
f 17  patients  had  GI  symptoms,  and  UDE  evidenced  gastritis
n three  cases  and  gastric  ulcer,  a  severe  ﬁnding,  in  four.
eriod  of  selective  prostaglandin  inhibitor
ineteen  patients  received  celecoxib,  during  a  median  of
5 months  (8-144).  An  increase  was  observed  in  height-for-
ge Z-score  from  -2.4  ±  -1.7  to  1.8  ±1.3  (p  =  0.02)  and  in
eight-for-age Z-score  from  -1.3  ±  1.5  to  -0.81  ±  1.2  (p  =
.01), as  well  as  a  reduction  in  creatinine  clearance  from
47 ±  52  to  119  ±  31  mL/min/1.73m2BS  (p  =  0.04).  Nine
atients presented  with  hyperﬁltration  at  the  beginning  of
reatment; at  the  end,  hyperﬁltration  was  detected  in  only
wo patients.  Seven  of  19  patients  presented  GI  symptoms,
ut UDE  evidenced  mild  gastritis  in  three  cases  and  no  case
f ulcer.
Comparing indomethacin  with  celecoxib,  positive  ﬁnd-
ngs in  UDE  were  more  present  in  indomethacin  group,
lthough not  signiﬁcant  (p  =  0.06);  however,  indomethacin
as associated  with  more  severe  compromise.  During  the
reatment with  celecoxib,  no  patient  developed  gastric
lcer.
eriod  of  ACEi  treatment
ive  patients  received  enalapril  by  median  of  23  months  (3-
0)  in  a  dosage  of  0.2  ±  0.1  mg/kg/d,ym  divided  in  two
oses, despite  we  have  tried  in  6;  one  patient  presented
evere hypotension  and  the  drug  was  withdrawn.  No  sig-
iﬁcant changes  were  observed  in  height-for-age  Z-score
median at  the  beginning  of  treatment  =  -2.5  [-4.3  to  -2.2];
edian at  the  end  =  -3.0  [-3.9  to  -1.21];  p  =  0.8),  nor  in  the
eight-for-age Z-score  (median  at  the  beginning  of  treat-
ent =  -2.1  [-2.7  to  -0.9];  median  at  the  end=  -2.7  [-3.8  to
0.3]; p  =  0.4).  The  creatinine  clearance  showed  no  statisti-
ally signiﬁcant  differences,  from  median  150  (107-183)  to
38 (62-160)  (p  =  0.18);  however,  a  decrease  was  observed
n four  patients,  one  of  whom  below  90  mL/min/1.73m2BS.
n this  case,  the  dose  of  enalapril  was  reduced.
Fig.  1  presents  the  weight-for-age  Z-score,  Fig.  2  shows
he height-for-age  Z-score  at  the  beginning  and  at  the  end  of
he treatment  with  each  drug.  Fig.  3  presents  the  creatinine
learance during  the  treatment  with  each  drug.
roteinuria  during  each  drug
even  patients  developed  microalbuminuria  during  treat-
ent with  indomethacin;  in  ﬁve  patients,  the  problem
esolved when  their  treatment  was  converted  to  celecoxib;
owever, four  patients  developed  microalbuminuria  during
he use  of  celecoxib.  Patients  with  proteinuria  had  their
reatment converted  to  ACEi,  and  presented  a  signiﬁcant
eduction: median  was  76.2%  (62.8%-80.6%).
Table  1  presents  the  average  of  serum  potassium,  sodium,
nd bicarbonate  levels  of  patients  during  each  drug  and  the
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Figure  1  Z-score  for  weight  at  the  beginning  and  at  the  end  of  the  treatment  with  different  medications.  Bars  represent  95%  CI
(conﬁdence  interval).
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Figure  3  Creatinine  clearance  according  to  Schwartz’s  formula  of  Bartter  syndrome  patients,  at  the  beginning  and  at  the  end  of
treatment  with  each  medication.  Bars  represent  95%  CI.
Table  1  Serum  potassium,  sodium,  bicarbonate,  and  potassium  supplementation  in  20  Bartter  syndrome  patients  during  dif-
ferent  schedules  of  treatment.
Variables  Indomethacin  Selective  NSAIDS  ACEi
Serum  potassium
mEq/L  (median  ±  SD)
3.3  ±  0.4  3.5  ±  0.4  3.5  ±  0.2
Serum  sodium
mEq/L  (median  ±  SD)
138 ±  3  138  ±  2  137  ±  3
Serum  bicarbonate  (median  ±  SD)  26.7  ±  1.7  26.8  ±  2.1  25.4  ±  1.8
Potassium  supplementation
mEq/kg/day  (median  ±  SD)
6.6 ±  3.2  6.8  ±  4.4  11.0  ±  4.6ACEi, angiotensin conversion enzyme inhibitor; NSAIDS, non-steroidal anti-inﬂammatory drugs; SD, standard deviation.
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mount  of  potassium  supplementation  including  data  from
ach six  months.  No  signiﬁcant  differences  were  observed
n serum  potassium,  sodium,  and  bicarbonate  levels  during
he use  of  the  three  drugs.  No  signiﬁcant  differences  were
bserved between  the  amount  of  potassium  supplementa-
ion during  the  use  of  indomethacin  and  celecoxib  (p  =  0.8).
lthough no  signiﬁcant  differences  were  detected  in  the
mount of  potassium  supplementation  during  indomethacin
nd ACEi  (p  =  0.09)  and  celecoxib  and  ACEi  (p  =  0.2),  a  ten-
ency to  supplement  a  larger  amount  of  potassium  during
CEi was  observed,  as  seen  in  Table  1.
iscussion
n  BS,  an  over  activation  of  renin-angiotensin-aldosterone
ystem  (RAAS)  and  an  over  production  of  PGs  can  be
bserved. Those  ﬁndings  are  the  result  of  sodium,  chlo-
ide, and  potassium  urinary  wasting.  Therefore,  the
ecommended treatment  has  been  based  on  potassium  sup-
lementation, a  PGs  inhibitor;7,8 spironolactone1 is  also  an
ption, but  with  transient  effect,  and  ACEi  has  been  used  in
ome studies.9
Indomethacin  has  been  long  employed  in  the  treat-
ent of  these  patients.  Studies  have  demonstrated  that
ith indomethacin,  spironolactone,  and  potassium  chloride
upplementation and,  sometimes,  sodium  chloride  supple-
entation, patients  experience  improvement  in  growth
peed, weight  gain,  and  metabolic  stability.10 However,
here are  signiﬁcant  GI  effects  resulting  from  inhibition  of
yclooxygenase (Cox)  1.4 These  data  are  in  accordance  with
he present  ﬁndings  during  the  use  of  indomethacin.4 As  an
ption, selective  inhibitors  of  Cox  (Cox-2  inhibitors  more
han Cox-1,  such  as  celecoxib)  have  been  employed,  seek-
ng a  renal  effect,  with  reduction  of  undesirable  GI  effects.11
he  majority  of  studies  have  observed  that  sNSAIDs  are  asso-
iated with  a  lower  risk  of  ulcers  and  complications  than
sNSAIDs.12 In  the  present  study,  celecoxib  promoted  a  bet-
er compliance  to  the  treatment  and  a  reduction  in  severe
I involvement  (such  as  gastric  ulcers),  with  metabolic
nd electrolyte  stability  and  improvement  in  growth  speed
nd weight  gain.4 In  addition,  celecoxib  was  associated
ith a  lower  rate  of  hyperﬁltration  than  indomethacin.
yperﬁltration  is  associated  to  focal  glomerulosclerosis
ccurrence.
Thus, the  use  of  celecoxib  can  be  a  good  option  for  BS
atients, although  larger  studies  are  needed  in  order  to
rove its  safety  and  efﬁcacy.
In  the  last  decade,  an  increase  in  cardiovascular  events
as been  observed  during  the  use  of  COX-2  selective
nhibitors. Those  studies  were  made  in  patients  with  high
ardiovascular risk,  such  as  the  elderly  or  those  in  use  of
cetylsalicylic acid.  There  are  few  long-term  trials  evalu-
ting cardiovascular  safety  of  celecoxib,  but  no  conclusion
an be  drawn.13,14 The  balance  between  the  production
f prostacyclin  and  thromboxane  is  thought  to  play  a  role
n regulation  of  platelet  aggregation  and  in  vascular  tone.
S is  associated  with  overproduction  of  prostaglandins  and
hromboxane.15 It  can  thus  be  speculated  that  the  side-
ffect on  cardiovascular  system  is  not  a  risk  factor  in  BS
atients. However,  no  such  well-deﬁned  clinical  trials  have
een conducted.Nascimento  CL  et  al.
Long-term  follow-up  of  patients  under  the  use  of  sNSAID
as demonstrated  that  alongside  its  beneﬁcial  effect,
atients can  develop  proteinuria,  which  is  an  aggravating
o the  progression  to  end-stage  renal  disease.2 In  this  situ-
tio,n an  RAAS  inhibitor  can  be  used  as  a  replacement  drug
o NSAID.  Few  reports  have  been  published  on  the  use  of
hese drugs.16 Seyberth  &  Schlingmann2 stated  that  ‘‘only
n the  case  of  persistent  hypokalemia  (plasma  potassium
3.0 mEq/L)  that  occurs  despite  adequate  and  tolerated
nhibition of  prostaglandin  synthesis  and  salt  and  potassium
upplementation, one  might  consider  the  use  of  drugs  that
nterfere with  the  RAAS’’.  However,  close  monitoring  of
enal function  and  blood  pressure  is  mandatory.  This  supple-
ental therapy  might  have  an  additional  beneﬁcial  effect  on
roteinuria.17
In  the  present  study,  in  patients  who  developed  protein-
ria during  treatment  with  celecoxib,  the  replacement  by
nalapril provided  electrolyte  and  metabolic  balance  with
igniﬁcant reduction  of  proteinuria.  In  addition,  good  toler-
nce and  compliance  were  observed  with  this  treatment.  It
s noteworthy  that  the  administration  of  an  inhibitor  of  RAAS
n these  patients  can  determine  severe  hypotension.  Thus,
he recommendation  is  that  the  transition  from  NSAID  to  a
AAS inhibitor  should  be  performed  in  the  hospital  setting,
nder medical  supervision.
NSAIDs, both  indomethacin  and  celecoxib,  are  effective
n treating  BS.  The  latter  has  demonstrated  beneﬁts  on
everity of  GI  tract  involvement  and  decreasing  in  hyperﬁl-
ration. However,  the  safety  proﬁle  of  celecoxib  may,  in  the
uture, allow  for  its  use  as  ﬁrst  drug  for  the  treatment  of  BS.
n patients  who  develop  proteinuria,  enalapril  was  effective
n reducing  it.  Thus,  it  is  suggested  to  start  the  treatment
ith celecoxib  and  if  necessary  replacing  it  by  ACEi.
This  study  has  some  limitations,  such  as  the  small  number
f patients  and  lack  of  a  genetic  assessment.  Randomized,
arger and  controlled  studies  are  needed  to  conﬁrm  the
resent data.  However,  it  is  a rare  disease,  and  the  present
tudy had  one  of  the  largest  series  in  the  literature.
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